Skip to main
PEPG
PEPG logo

PepGen Inc (PEPG) Stock Forecast & Price Target

PepGen Inc (PEPG) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 0%
Sell 20%
Strong Sell 0%

Bulls say

PepGen Inc., a clinical-stage biotechnology company, is poised for significant growth, with shares currently trading around $4, indicating potential upside should upcoming multi-dose data demonstrate a favorable risk/benefit profile. The company's Enhanced Delivery Oligonucleotide platform has shown impressive preclinical results, with a reported splicing correction of 53.7% for its product PGN-EDO51, surpassing competitors and suggesting a potential for meaningful enhancements in muscle performance. Additionally, the successful demonstration of efficacy in its pipeline, particularly in neuromuscular and neurologic disease treatments, positions PepGen advantageously within the biotech sector, reflecting a strong potential for future value appreciation.

Bears say

PepGen Inc. has reduced its target price to $8 per share amid concerns about its ability to execute commercially and meet or exceed expectations, which could negatively impact its stock performance. Despite the promising data regarding its DM1 therapy and its Enhanced Delivery Oligonucleotide platform, PepGen faces significant competitive pressures that may hinder its market positioning. Moreover, the company may experience delays or the termination of development campaigns if it fails to access the capital markets effectively, further contributing to a negative outlook on its financial prospects.

PepGen Inc (PEPG) has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 20% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PepGen Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PepGen Inc (PEPG) Forecast

Analysts have given PepGen Inc (PEPG) a Buy based on their latest research and market trends.

According to 5 analysts, PepGen Inc (PEPG) has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PepGen Inc (PEPG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.